Andere Sprachen Lexeo Therapeutics, Inc.

Aktien

A3EXD2

US52886X1072

LXEO

Markt geschlossen - Nasdaq Andere Börsenplätze 21:59:44 04.06.2024			% 5 Tage	% 1. Jan.
17,1 ^USD	+0,29 %		+14,00 %	+27,42 %

09.05.	Lexeo Therapeutics, Inc. meldet Ergebnis für das erste Quartal bis zum 31. März 2024	CI
22.04.	Lexeo Therapeutics, Inc. gibt bekannt, dass Bernard Davitian sich nicht zur Wiederwahl als Direktor stellen wird	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Lexeo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09.05.
Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights	09.05.
Lexeo Therapeutics to Participate in Upcoming Investor Conferences	07.05.
Certain Options of Lexeo Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.	01.05.
Certain Common Stock of Lexeo Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.	01.05.
Lexeo Therapeutics Signs License Deal With Cornell for Potential Friedreich Ataxia Cardiomyopathy Drug	22.04.
Lexeo Therapeutics, Inc. Announces Not to Stand for Reelection of Bernard Davitian as Director	22.04.
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy	22.04.
LEXEO THERAPEUTICS GRANTED FDA FAST TRACK DESIGNATION FOR LX2006, AN AAV-BASED GENE THERAPY CANDIDATE FOR THE TREATMENT OF FRIEDREICH'S ATAXIA CARDIOMYOPATHY	17.04.
Lexeo Says AAV-Based Gene Therapy Candidate Gets US FDA's Fast Track Designation for Friedreich's Ataxia Cardiomyopathy	16.04.
Lexeo Gets FDA Fast-Track Designation for LX2006 in Friedreich's Ataxia Cardiomyopathy	16.04.
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy	16.04.
Lexeo Therapeutics, Inc. Announces the U.S. Food and Drug Administration Grants Fast Track Designation for LX2006, an Aav-Based Gene Therapy Candidate for the Treatment of Friedreich?s Ataxia Cardiomyopathy	16.04.
Lexeo Therapeutics, Inc.(NasdaqGM:LXEO) added to S&P Global BMI Index	18.03.
Lexeo Therapeutics Raises $95 Million Via Private Placement of Shares	13.03.
Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing	13.03.
Lexeo Therapeutics, Inc. announced that it has received $94.999833 million in funding from a group of investors	13.03.
Lexeo Therapeutics' Q4 Net Loss Narrows; Cash Runway Extended to 2027 -- Shares Jump Pre-Bell	11.03.
LEXEO: ENTERED INTO COMMON STOCK PURCHASE AGREEMENT TO…	11.03.
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights	11.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Lexeo Therapeutics, Inc.

Aktien

A3EXD2

US52886X1072

LXEO

Andere Sprachen

Filter